In addition, research confirmed that TP53 mutations are associated with chemoresistance in colorectal cancer patients, which may contribute to the recurrence of liver metastases and poor efficacy of subsequent chemotherapy in this patient (21). This evidence concerns the gene TP53 and colorectal cancer.